R&D Views & Analysis | pharmaphorum

Views & Analysis

Propelling clinical research into the 21st century

Two and a half years ago, Covid-19 began to infect hundreds, then thousands, then millions of people, and was eventually declared a global pandemic.

Views & Analysis

Capturing progress in haemophilia care

If we look back just 70 years, the prognosis for patients with haemophilia was remarkably different to what it is today.

Views & Analysis

Pandemic boost to decentralised trials is here to stay

Due to the pandemic, decentralised trial solutions made the shift from an emerging trend to a crucial element of drug development.

Views & Analysis

Artificial Intelligence for better antibody drugs: ready for...

The potential of monoclonal antibodies (mAbs) as therapies is indisputable. The current mAbs market is expected to be around ~USD 150 billion.

Views & Analysis

Why blockchain is big pharma’s big focus

To address the supply chain vulnerabilities of the pharma industry, an innovative, collaborative blockchain-based system could help to keep track of drugs in transit and ensure they are sto

Views & Analysis

Making new product planning for life science more effective ...

The sooner a human-centred perspective is applied to the development of either a drug or device product, the more likely the product will be adopted and used because it’s been designed arou

Propelling clinical research into the 21st century

Capturing progress in haemophilia care

Pandemic boost to decentralised trials is here to stay

Artificial Intelligence for better antibody drugs: ready for...

Why blockchain is big pharma’s big focus

Making new product planning for life science more effective ...

Aspen, Bambusa close IPOs as Corxel takes SPAC route

Discover a new era of healthcare panel engagement: Grounded ...

Views & Analysis

Editor's Picks